This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

LOUIS W. GRANIRER, M.D.

AMA Arch Derm. 1958;77(6):722-724.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Recently antimalarial drugs have been shown to produce beneficial effects in rheumatoid arthritis. The most widely publicized of these drugs is 7-chloro-4-(4-diethylamino-1-methylbutylamino) quinoline diphosphate, or chloroquine (Aralen). In toxicity studies reactions from chloroquine are reported as "mild" and to date have been transitory in nature, disappearing completely either on cessation or continuance of therapy with full or reduced dosage. Chloroquine is cumulative in action, arid several weeks are required for it to exert the therapeutic effects. The usual dose is 250 mg. daily as a single dose. At least 4 to 12 weeks of therapy are required before the effects can be properly evaluated. Skin eruptions have been reported as generally mild.^1,2

The object of this paper is to report a more serious type of reaction to chloroquine manifested by severe purpura, edema, erythema, and exfoliative dermatitis.

Report of a Case

A 58-year-old woman was treated . . . [Full Text PDF of this Article]

Author Affiliations
Jamaica, Long Island, N. Y.

Footnotes
Received for publication Jan. 14, 1958.

The Arthritis Clinic and Department of Medicine, Queens General Hospital.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?